When people search Lilly tirzepatide, they are usually mapping who makes what in the GLP-1 landscape. This page lays out Eli Lilly's tirzepatide brands and their FDA indications, compares the portfolio with Novo Nordisk's molecular strategy, and covers the gene variants that sit upstream of every GLP-1 pathway compound.

Eli Lilly markets tirzepatide as Mounjaro and Zepbound, alongside dulaglutide as Trulicity. This guide maps the FDA indications, the mechanism that makes tirzepatide distinct, how it compares with Novo Nordisk, cost positioning, shared safety notes, and the genetics PlexusDx focuses on.

People searching Lilly weight loss drug usually want to know which specific product carries a weight-management indication. This page clarifies where Zepbound fits, explains the GIP/GLP-1 class biology behind it, walks through cost and safety at the class level, and covers the genetics that sit upstream of the pathway.

Mounjaro is one product in Eli Lilly's broader GLP-1 lineup. This guide maps the portfolio, including Mounjaro, Zepbound, Trulicity, and the investigational pipeline, compares Lilly's dual-incretin strategy to Novo Nordisk, covers shared cost and safety, and adds the genetic context that sits upstream of every brand.

Eli Lilly is one of two companies that dominate the GLP-1 landscape. This PlexusDx overview covers its portfolio and pipeline, how its products compare to Novo Nordisk, cost positioning, shared class safety, and the genetic variables upstream of every compound regardless of manufacturer.